These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
424 related articles for article (PubMed ID: 31188761)
1. The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome. Chatzis P; Tziomalos K; Pratilas GC; Makris V; Sotiriadis A; Dinas K Folia Med (Plovdiv); 2018 Dec; 60(4):512-520. PubMed ID: 31188761 [TBL] [Abstract][Full Text] [Related]
2. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological Treatment for Obesity in Adults: An Umbrella Review. Khalil H; Ellwood L; Lord H; Fernandez R Ann Pharmacother; 2020 Jul; 54(7):691-705. PubMed ID: 31958967 [No Abstract] [Full Text] [Related]
4. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618 [TBL] [Abstract][Full Text] [Related]
5. Diet, physical exercise and Orlistat administration increase serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS). Vosnakis C; Georgopoulos NA; Rousso D; Mavromatidis G; Katsikis I; Roupas ND; Mamali I; Panidis D Gynecol Endocrinol; 2013 Mar; 29(3):242-5. PubMed ID: 23194076 [TBL] [Abstract][Full Text] [Related]
6. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Song J; Ruan X; Gu M; Wang L; Wang H; Mueck AO Gynecol Endocrinol; 2018 May; 34(5):413-417. PubMed ID: 29172796 [TBL] [Abstract][Full Text] [Related]
7. The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome. Panidis D; Tziomalos K; Papadakis E; Chatzis P; Kandaraki EA; Tsourdi EA; Katsikis I Clin Endocrinol (Oxf); 2014 Mar; 80(3):432-8. PubMed ID: 23909452 [TBL] [Abstract][Full Text] [Related]
8. Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome. Koiou E; Tziomalos K; Katsikis I; Delkos D; Tsourdi EA; Panidis D Hormones (Athens); 2013; 12(4):559-66. PubMed ID: 24457404 [TBL] [Abstract][Full Text] [Related]
9. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome. Tzotzas T; Karras SN; Katsiki N Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008 [TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Tak YJ; Lee SY Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104 [TBL] [Abstract][Full Text] [Related]
11. Effects of orlistat on serum androgen levels among iranian obese women with polycystic ovarian syndrome. Salehpour S; Hosseini S; Nazari L; Saharkhiz N; Zademodarres S JBRA Assist Reprod; 2018 Sep; 22(3):180-184. PubMed ID: 29757582 [TBL] [Abstract][Full Text] [Related]
12. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. Barrea L; Pugliese G; Muscogiuri G; Laudisio D; Colao A; Savastano S Minerva Endocrinol; 2020 Jun; 45(2):127-137. PubMed ID: 32643356 [TBL] [Abstract][Full Text] [Related]
13. Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis. Wang FF; Wu Y; Zhu YH; Ding T; Batterham RL; Qu F; Hardiman PJ Obes Rev; 2018 Oct; 19(10):1424-1445. PubMed ID: 30066361 [TBL] [Abstract][Full Text] [Related]
14. Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain. Howland RH J Psychosoc Nurs Ment Health Serv; 2015 Jun; 53(6):19-22. PubMed ID: 26091546 [TBL] [Abstract][Full Text] [Related]
16. Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss. Spanos N; Tziomalos K; Macut D; Koiou E; Kandaraki EA; Delkos D; Tsourdi E; Panidis D Obes Facts; 2012; 5(4):495-504. PubMed ID: 22854419 [TBL] [Abstract][Full Text] [Related]
17. Overview of new antiobesity drugs. Hainer V Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293 [TBL] [Abstract][Full Text] [Related]
18. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. Cena H; Chiovato L; Nappi RE J Clin Endocrinol Metab; 2020 Aug; 105(8):e2695-709. PubMed ID: 32442310 [TBL] [Abstract][Full Text] [Related]
19. Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? Pugliese G; de Alteriis G; Muscogiuri G; Barrea L; Verde L; Zumbolo F; Colao A; Savastano S J Endocrinol Invest; 2023 Sep; 46(9):1761-1774. PubMed ID: 37093453 [TBL] [Abstract][Full Text] [Related]
20. Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility. Panidis D; Tziomalos K; Papadakis E; Vosnakis C; Chatzis P; Katsikis I Endocrine; 2013 Dec; 44(3):583-90. PubMed ID: 23625194 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]